<DOC>
	<DOCNO>NCT00501371</DOCNO>
	<brief_summary>Phase III , Randomized , double-blind , parallel placebo-controlled study . Two arm : MCS ( 30mg/day ) vs. placebo . Subproject MCS-2 : alpha-blocker naïve subject Subproject MCS-3 : subject respond poorly alpha-blocker</brief_summary>
	<brief_title>MCS Treating Lower Urinary Tract Symptoms ( LUTS ) Suggestive Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>For MCS-2 This double-blind , randomize , placebo-controlled , parallel study eligible male subject ( age 40 , N=188 ) , two-week washout period , randomize 1:1 ratio receive either MCS 30 mg/day placebo 12 week . Group A : MCS 30 mg/day 12 week Group B : placebo 12 week Subjects limit currently treat medically BPH LUTS alpha-blocker , anti-cholinergics , 5-alpha reductase inhibitor , hormonal therapeutic agent . For treatment arm , 85 subject eligible final per protocol analysis recruit . Concerning expect dropout rate 10 % , 188 subject total recruit onto study . For MCS-3 This double-blind , randomize , placebo-controlled , add-on , parallel study eligible male subject ( age 40 , N=242 ) , two-week washout period , randomize 1:1 ratio receive either MCS 30 mg/day plus alpha-blocker placebo plus alpha-blocker 12 week . Group A : alpha-blocker plus MCS 30 mg/day Group B : alpha-blocker plus placebo Subjects limit currently treat medically BPH LUTS anti-cholinergics , 5-alpha reductase inhibitor , hormonal therapeutic agent . For treatment arm , 220 subject eligible final per protocol analysis recruit . Concerning expect dropout rate 10 % , 242 subject total recruit onto study . All participate subject advise maintain normal diet joining study . However , participate subject advise refrain extra source carotenoid supplementation MCS extract make capsule , soft gel , crude granule extract .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Inclusion criterion subproject MCS2 Age ≧ 40 year old . Not treated BPH LUTS Alphablocker , anticholinergic , 5alpha reductase inhibitor , hormonal agent . PSA≦4 ng/ml within 4 week V1 pathologicallyproven prostate cancer . No known malignancy , except cancer without sign recurrence &gt; 5 year need anticancer treatment . AST/ALT≦3X UNL . creatinine≦3X UNL . Subjects sign inform consent form . Exclusion criterion Subjects ' LUTS BPHrelated associate condition urethral stricture , prostatitis , neurogenic bladder , pelvic treatment procedure . Have treat pelvis irradiation pelvic surgery . Plan undergo invasive procedure within study period , , prostate surgery , prostate biopsy , cystourethroscopy , pelvic surgery , laparotomy , procedure need urethral catheterization . Participating another investigational agent study past 12 week go study period . Active infection inflammation . Considered ineligible investigator . Inclusion criterion subproject MCS3 Age≧40 year old . The alphablocker dosage use high subject tolerate . No known malignancy , except cancer without sign recurrence &gt; 5 year need anticancer treatment . PSA≦10.0 ng/ml without pathologicallyproven prostate cancer cancer . Prostate biopsy mandatory &gt; 12 week screen , PSA is≧4 ng/ml rule prostate cancer . AST/ALT≦3X UNL . Creatinine≦3X UNL . Subjects sign inform consent form . Exclusion criterion Subjects ' LUTS BPHrelated associate condition urethral stricture , prostatitis , neurogenic bladder , pelvic treatment procedure . Subjects treat pelvis irradiation pelvic surgery . PSA &gt; 10.0 ng/ml , abnormal DRE prostate suspicion prostate malignancy . However , negative prostate biopsy allow . Active infection inflammation . Considered ineligible investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>MCS</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom score</keyword>
	<keyword>Voiding</keyword>
	<keyword>Alpha-blockers</keyword>
</DOC>